Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
06 mai 2019 21h39 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces New Employment Inducement Grant
10 janv. 2019 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
06 janv. 2019 11h38 HE
|
Adamas Pharmaceuticals, Inc.
-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700...
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
18 déc. 2018 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Reports Third Quarter 2018 Financial Results
01 nov. 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
08 oct. 2018 08h30 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two yearsResults show a comparable 35% reduction from baseline in dyskinesia and OFF...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
04 oct. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
24 mai 2018 09h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release...
Adamas Reports First Quarter 2018 Financial Results
03 mai 2018 16h05 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S....
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
22 févr. 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended...